Literature DB >> 18765108

Antiretroviral therapy: when to start and which drugs to use.

Albert M Anderson1, Jeffrey L Lennox.   

Abstract

US guidelines for treating HIV infection now advocate antiretroviral therapy (ART) for all HIV-infected patients who have CD4(+) T-cell counts less than 350 cells/muL. Treatment is recommended for all pregnant women and patients with AIDS-defining illnesses. At least one major guideline recommends ART for all patients with HIV--associated symptoms. Current first-line treatment for ART-naïve individuals consists of a combination of three agents: two nucleoside reverse transcriptase inhibitors plus either one ritonavir-boosted protease inhibitor or one nonnucleoside reverse transcriptase inhibitor (NNRTI). Although first-line therapies for HIV-infection provide excellent rates of virologic control, ART toxicities remain a challenge.

Entities:  

Year:  2008        PMID: 18765108     DOI: 10.1007/s11908-008-0053-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  35 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 2.  An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.

Authors:  John A Bartlett; Michael J Fath; Ralph Demasi; Ashwaq Hermes; Joseph Quinn; Elsa Mondou; Franck Rousseau
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

3.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Authors:  P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

6.  A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

Authors:  Ulrik B Dragsted; Jan Gerstoft; Mike Youle; Zoe Fox; Marcello Losso; Jorge Benetucci; Dushyantha T Jayaweera; Armin Rieger; Johan N Bruun; Antonella Castagna; Brian Gazzard; Sharon Walmsley; Andrew Hill; Jens D Lundgren
Journal:  Antivir Ther       Date:  2005

7.  Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.

Authors:  A Mocroft; B Ledergerber; J P Viard; S Staszewski; M Murphy; A Chiesi; A Horban; A-B E Hansen; A N Phillips; J D Lundgren
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

8.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects.

Authors:  Scott E Kellerman; Debra L Hanson; A D McNaghten; Patricia L Fleming
Journal:  J Infect Dis       Date:  2003-08-05       Impact factor: 5.226

10.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

View more
  2 in total

Review 1.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

Review 2.  The macrophage: a therapeutic target in HIV-1 infection.

Authors:  Amit Kumar; Georges Herbein
Journal:  Mol Cell Ther       Date:  2014-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.